Clinical Trial

Registry to Collect Data on Patients Undergoing Segmental Mandibular Defect Reconstruction Following Oral Squamous Cell Carcinoma Resection and Drugs-induced Osteonecrosis

Recruiting
View on ClinicalTrials.gov →
Summary
Prospective will be collected in a minimum of 300 patients presenting with an acquired segmental mandibular defect ≥ 2 cm secondary to OSSC removal and drugs-induced osteonecrosis, and who require mandibular reconstruction.
Protocol Amendment History 18 amendments
This ClinicalTrials.gov record has been amended 18 times since 2019-09-18; most recent amendment 2025-08-28.
Status change: Not Yet Recruiting → Recruiting 2022-09-12
Trial Details
NCT Number NCT04098146
Lead Sponsor AO Innovation Translation Center
Conditions Mandibular Reconstruction, Segmental Mandibular Defects
Enrollment 300 participants
Start Date 2022-09-12
Primary Completion 2030-06-30 (estimated)
Study Completion 2030-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-09-04